Zevin Asset Management buys $2,427,577 stake in Meridian Bioscience (VIVO)

Meridian Bioscience (VIVO) : Zevin Asset Management scooped up 4,230 additional shares in Meridian Bioscience during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 8, 2016. The investment management firm now holds a total of 124,555 shares of Meridian Bioscience which is valued at $2,427,577.Meridian Bioscience makes up approximately 0.65% of Zevin Asset Management’s portfolio.

Other Hedge Funds, Including , Neuberger Berman Group sold out all of its stake in VIVO during the most recent quarter. The investment firm sold 788,597 shares of VIVO which is valued $15,322,440. Cambridge Investment Research Advisors added VIVO to its portfolio by purchasing 10,021 company shares during the most recent quarter which is valued at $194,708.American Capital Management Inc reduced its stake in VIVO by selling 6,500 shares or 13.42% in the most recent quarter. The Hedge Fund company now holds 41,950 shares of VIVO which is valued at $814,669. Meridian Bioscience makes up approx 0.07% of American Capital Management Inc’s portfolio.California State Teachers Retirement System reduced its stake in VIVO by selling 934 shares or 1.06% in the most recent quarter. The Hedge Fund company now holds 87,449 shares of VIVO which is valued at $1,698,260.

Meridian Bioscience closed down -0.09 points or -0.46% at $19.3 with 1,64,816 shares getting traded on Monday. Post opening the session at $19.49, the shares hit an intraday low of $19.3 and an intraday high of $19.67 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Meridian Bioscience reported $0.21 EPS for the quarter, missing the analyst consensus estimate by $ -0.01 based on the information available during the earnings call on Jul 28, 2016. Analyst had a consensus of $0.22. The company had revenue of $50.70 million for the quarter, compared to analysts expectations of $52.87 million. The company’s revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.22 EPS.

Meridian Bioscience Inc. (Meridian) is an integrated life science company. The Company is engaged in developing manufacturing selling and distribution of clinical diagnostic test kits for certain gastrointestinal viral respiratory and parasitic infectious diseases; the manufacture and distribution of bulk antigens antibodies polymerase chain reaction (PCR)/ quantitative polymerase chain reaction (qPCR) reagents nucleotides competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers and the contract development and manufacture of proteins and other biologicals under cyclic guanosine monophosphate (cGMP) conditions for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines. The Company operates in two segments: Diagnostics and Life Science.

Leave a Reply

Meridian Bioscience - Is it time to Sell?

Top Brokerage Firms are advising their investors on Meridian Bioscience. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.